Blockade of alpha-adrenergic receptors by analogues of phosphatidylcholine.
The experimental evidence reviewed in this article suggests that the kidneys may have an additional function in regulating blood pressure besides their role in controlling both blood volume by urine formation and the relative state of vasoconstriction by the renin-angiotensin system. That is, the kidneys may have an additional influence upon the vasculature of a hormonal vasodilating system. The interstitial cells of the renal medulla appear to be mediating this activity and lipid compounds have been extracted from the renal medulla which display depressor activity. One such compound, the antihypertensive polar renomedullary lipid (APRL), has been demonstrated to consist of specific alkyl ether analogues of phosphatidylcholine. The vascular responses to these compounds include vasodilation of both arterioles and venules, rapid lowering of arterial blood pressure with little or no tachycardia, increased depressor activity in hypertensive animals, and blockade of vascular smooth muscle alpha 1-adrenergic receptors. Most recently, APRL and a synthetic analogue, 1-0-octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine, have been used to demonstrate alpha-adrenergic receptor blockade on a smooth muscle cell line (DDT1) by radioligand assays. This action may be due to the insertion of these compounds into cell membranes causing subsequent steric interactions and blockade of the alpha-adrenergic receptor.
D000107:Acetylation; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001160:Arterioles / Q000187:drug effects; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume; D002460:Cell Line; D004088:Dihydroergotoxine / Q000378:metabolism; D005997:Glycerylphosphorylcholine / Q000494:pharmacology; D006801:Humans; D006977:Hypertension, Renal / Q000503:physiopathology; D007668:Kidney / Q000502:physiology*; D007679:Kidney Medulla / Q000502:physiology; D009130:Muscle, Smooth / Q000378:metabolism; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010713:Phosphatidylcholines / Q000494:pharmacology*; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects; D014680:Veins / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D010713:Phosphatidylcholines; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D004088:Dihydroergotoxine; D005997:Glycerylphosphorylcholine; D009638:Norepinephrine